A Phase 2/3 interventional study of Placebo and Picankibart in Psoriatic Arthritis, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic with a site in China — 10 open to participants now, 19 under way, 11 of them phase 3. Arthritis, Psoriatic · China.
Among the 34 studies in Arthritis, Psoriatic with a site in China, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 15 of the 18 other live ones, and was the 29th registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →10 of the 34 studies in Arthritis, Psoriatic with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Takeda · Sites in China, United States, Argentina and 17 more countries
Ages 18+
InventisBio Co., Ltd · Sites in China
Ages 18–70
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 15 more countries
Ages 3+
Hansoh BioMedical R&D Company · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Arthritis, Psoriatic studies recruiting now, 52 (59%) set no upper age limit and 27 (31%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 15 · Phase 4 2
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 222 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 208 across the 27 interventional studies, 400 across the 7 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Innovent Biologics, Inc. has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Psoriatic with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957550Phase 3Jiangsu HengRui Medicine Co., Ltd.To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | 2026-12-13 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
| NCT07321873Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | 2027-06-28 |
| NCT07406035Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 34 studies in Arthritis, Psoriatic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA). The study consists of two stages: Phase II dose-finding (n=90) and Phase III confirmatory (n=132). Participants will receive subcutaneous (SC) injections of either picankibart (200mg) or placebo with different dosing schedules, with placebo crossover to active treatment at Week 26. The Phase II portion will identify optimal dosing for Phase III, which will confirm efficacy. The study will evaluate improvements in joint symptoms, physical function, quality of life, and skin manifestations. Primary endpoint is percentage of participants who achieved an American College of Rheumatology (ACR) 20 Response at Week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive picankibart SC at each scheduled dosing timepoint with dosing interval 2.
Other: Placebo · Drug: Picankibart
Participants receive placebo SC at each scheduled dosing timepoint. Treatment of picankibart starts at Week 26.
Other: Placebo · Drug: Picankibart
Participants receive picankibart SC at each scheduled dosing timepoint with dosing interval 1.
Drug: Picankibart
Placebo administered SC at each scheduled dosing timepoint.
Picankibart administered SC at each scheduled dosing timepoint.
Percentage of participants who achieved an American College of Rheumatology (ACR) 20 response
The ACR20 response is defined as ≥20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥20% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).
Time frame: Week 26
Change from baseline in Disease Activity Score in 28 Joints (DAS28)-CRP score
The DAS28-CRP is a measure of disease activity based on swollen and tender joint counts in 28 joints, CRP and the participant's global assessment of disease activity. The range of DAS28-CRP score is 0-10. Higher score means more disease activity.
Time frame: Week 26, and from baseline to Week 56
Percentage of participants who achieved an ACR50 response
The ACR50 response is defined as ≥50% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥50% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).
Time frame: Week 26, and from baseline to Week 56
Percentage of participants who achieved an ACR70 response
The ACR70 response is defined as ≥70% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and ≥70% improvement in 3 of following 5 assessments: participant's assessment of pain using Visual Analog Scale (VAS; 0-100 millimeter \[mm\], 0 mm=no pain and 100 mm=worst possible pain), participant's global assessment of disease activity by using VAS (scale ranges from 0 mm to 100 mm, \[0 mm= very well to 100 mm= very poor\]), physician's global assessment of disease activity using VAS (scale ranges from 0 to 100), \[0 = no arthritis to 100 = extremely active arthritis\], participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and C-reactive protein (CRP).
Time frame: Week 26, and from baseline to Week 56
Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI measures improvement in physical function/disability. It is defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.
Time frame: Week 26, and from baseline to Week 56
Change from baseline in Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) score
The SF-36 Health determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100) and a positive change from Baseline indicates improvement.
Time frame: Week 26, and from baseline to Week 56
Enthesitis/dactylitis resolution rates
Percentage of participants with complete resolution of enthesitis (inflammation at tendon/ligament attachments) or dactylitis (sausage-digit swelling).
Time frame: Week 26, and from baseline to Week 56
Percentage of participants who achieved 75%Psoriasis Area and Severity Index 75 response
Percentage of participants who achieve at least 75% or 90% or 100% reduction in Psoriasis Area and Severity Index (PASI) score, assessing skin lesion severity in psoriatic arthritis patients.
Time frame: From baseline to Week 56
Change from baseline in van der Heijde-modified Total Sharp Score (vdH-mTSS)
The vdH-mTSS is a measure of change in joint health. X-rays of hands and feet are obtained at screening, Week 26 and Week 56. Totals for hands and feet for erosion scores (range 0 to 320) and joint space narrowing scores (range 0 to 208) were calculated and added to obtain the vdH-mTSS (range = 0 \[normal\] to 528 \[maximal disease\]). An increase in vdH-mTSS from baseline represents disease progression and/or joint worsening.
Time frame: Week 26 and Week 56
Percentage of participants who experienced adverse events (AEs)
An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment.
Time frame: From baseline to Week 56
Percentage of participants who experienced serious adverse events (SAEs)
An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome.
Time frame: From baseline to Week 56
Maximum plasma concentration (Cmax) of picankibart
Plasma concentration of picankibart is evaluated at each scheduled dosing timepoint. Cmax is the highest concentration of a drug in the blood.
Time frame: From baseline to Week 56
Area under the concentration-time curve (AUC) of picankibart
Plasma concentration of picankibart is evaluated at each scheduled dosing timepoint. AUC represents the area under the concentration-time curve and gives insight into the extent of exposure to a drug and its clearance rate from the body.
Time frame: From baseline to Week 56
Percentage of participants who developed anti-drug antibody (ADA)
ADAs are immune system-produced antibodies that specifically bind to therapeutic drugs, potentially altering their pharmacokinetics, efficacy, or safety.
Time frame: From baseline to Week 56
Percentage of participants who developed neutralizing antibody (NAb)
NAbs are ADAs that inhibit the drug's biological function by blocking target interaction.
Time frame: From baseline to Week 56
Started Dec 2025 (actual). Primary completion is estimated for Dec 2029, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Picankibart
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. →